Shoulder Innovations (NYSE:SI) Major Shareholder Sells $244,155.21 in Stock

Shoulder Innovations, Inc. (NYSE:SI) major shareholder Healthcare Holding B.V. Gilde sold 10,751 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $22.71, for a total value of $244,155.21. Following the completion of the transaction, the insider owned 2,321,452 shares in the company, valued at $52,720,174.92. This represents a 0.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Healthcare Holding B.V. Gilde also recently made the following trade(s):

• On Thursday, August 6th, Healthcare Holding B.V. Gilde sold 2,095 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.60, for a total value of $47,347.00.
• On Wednesday, August 5th, Healthcare Holding B.V. Gilde sold 7,338 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.64, for a total value of $166,132.32.
• On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.77, for a total value of $2,272,719.24.
• On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.73, for a total value of $455,372.82.
• On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The shares were sold at an average price of $23.36, for a total transaction of $659,803.20.

Shoulder Innovations Stock Performance

Shares of NYSE:SI opened at $20.54 on Friday. The firm’s 50 day simple moving average is $19.91 and its 200 day simple moving average is $16.07. Shoulder Innovations, Inc. has a fifty-two week low of $10.92 and a fifty-two week high of $24.59. The company has a market capitalization of $426.06 million and a price-to-earnings ratio of -10.70. The company has a debt-to-equity ratio of 0.11, a current ratio of 11.81 and a quick ratio of 10.04.

Shoulder Innovations (NYSE:SI) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.03. The firm had revenue of $16.71 million during the quarter. Shoulder Innovations had a negative net margin of 58.33% and a negative return on equity of 22.93%. As a group, sell-side analysts forecast that Shoulder Innovations, Inc. will post -1.67 earnings per share for the current year.

Institutional Trading of Shoulder Innovations

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Shoulder Innovations in the third quarter worth $28,000. Rhumbline Advisers bought a new position in Shoulder Innovations in the third quarter valued at $54,000. Wells Fargo & Company MN increased its stake in Shoulder Innovations by 66.3% in the 4th quarter. Wells Fargo & Company MN now owns 5,250 shares of the company’s stock valued at $75,000 after buying an additional 2,094 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Shoulder Innovations during the 4th quarter worth about $176,000. Finally, Blue Trust Inc. bought a new stake in Shoulder Innovations during the 1st quarter worth about $228,000.

Key Headlines Impacting Shoulder Innovations

Here are the key news stories impacting Shoulder Innovations this week:

• Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
• Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
• Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
• Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
• Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
• Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. UBS Group began coverage on Shoulder Innovations in a research note on Tuesday, July 28th. They set a “buy” rating and a $27.00 price objective on the stock. Weiss Ratings upgraded Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday. BTIG Research raised their price target on Shoulder Innovations from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $25.00 price objective (up from $19.00) on shares of Shoulder Innovations in a research report on Friday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.33.

Shoulder Innovations Company Profile

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.